Theriva Biologics says Nature Medicine publishes Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer
Bitget2026/10/01 02:35- Theriva Biologics reported Nature Medicine publication of detailed Phase 2b VIRAGE results for VCN-01 in metastatic pancreatic cancer.
- Results were previously presented; the publication follows peer review and positions the dataset for broader clinical and investor scrutiny.
- VCN-01 with standard gemcitabine and nab-paclitaxel showed better patient outcomes than chemotherapy alone, supporting continued development.
- Survival patterns and response timing were consistent with an immune-mediated effect, strengthening rationale for combination strategies.
- A Phase 2a VIRAGE2 study is underway to test more frequent repeat dosing; initial safety and pharmacodynamic data are expected in Q3 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Mortgage rates return to 7%, pending home sales in the US fall to nearly a twelve-year low
According to Freddie Mac data, the 30-year fixed mortgage rate has risen to 7.4%, the highest level in nearly three years. Data from real estate brokerage Redfin shows that the volume of existing home pending sales in September fell 4% month-on-month, marking the largest single-month drop in over three years and hitting the lowest level since 2014. Nearly one-fifth of sellers have reduced prices, and the home purchase contract cancellation rate has reached a record high of 14.5%. Inventory levels have risen to the highest since March 2020, but high financing costs continue to constrain transactions.
Mueller Water Products names Michael Morgan CFO, succeeding Melissa Rasmussen
GLD ETF Falls 0.6%
JPMorgan’s tokenized funds on Ethereum hold $844 million
Crypto prices
More
